Britain and America have secured a landmark trade agreement that will keep zero tariffs on British pharmaceutical shipments entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase expenditure on drugs through the NHS. This move guarantees that duties on these crucial exports will stay at zero for a duration of the next three years.
This deal comes after earlier threats to significantly raise import taxes on patented drug products, with increases mentioned as high as 100%.
"This agreement with the UK bolsters the global environment for innovative medicines and establishes much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Trade Significance
Drugs are one of the the United Kingdom's largest exports to the America, which is easily the biggest destination for large British pharmaceutical firms.
Trade data show that in the one-year period prior to September, the UK exported medicines totaling £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that span.
"This guarantee protects jobs, stimulates funding and sets the stage for the UK to emerge as a worldwide center for life sciences," a government official stated.
Key British Pledges
The deal entails several key changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must return to the NHS to control costs will be capped at fifteen percent. In the past, repayments were more than twenty percent.
Industry Background
The deal comes amid a long-running row between the sector and the ministers over spending levels and regulatory access.
These tensions were intensified by assertions that US consumers were paying a premium for the same drugs than patients in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been halted or cancelled, while major funding commitments have been announced toward US facilities.
One official stated that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
